Common TitleDOMONO
Official Title The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial
Phase Phase IV
ClinicalTrials.gov NCT02401828
Treatments
Dolutegravir

Dolutegravir
Tradename:TivicayOther Names:DTGClass:Integrase Inhibitors (INSTI)Categories Treatment-ExperiencedSwitch/SimplificationMonotherapy
Funding
Non-IndustryErasmus Medical Center
References
- Wijting I, Rokx C, Boucher C, et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV. 2017;4:e547-e554.